"Clozapine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.
| Descriptor ID |
D003024
|
| MeSH Number(s) |
D03.633.300.240.220
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Clozapine".
Below are MeSH descriptors whose meaning is more specific than "Clozapine".
This graph shows the total number of publications written about "Clozapine" by people in this website by year, and whether "Clozapine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 2 | 0 | 2 |
| 2001 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Clozapine" by people in Profiles.
-
Rahman T, Ash DM, Lauriello J, Rawlani R. Misleading Guidance From Pharmacogenomic Testing. Am J Psychiatry. 2017 Oct 01; 174(10):922-924.
-
Gerken AT, McGahee S, Keuroghlian AS, Freudenreich O. Consideration of Clozapine and Gender-Affirming Medical Care for an HIV-Positive Person with Schizophrenia and Fluctuating Gender Identity. Harv Rev Psychiatry. 2016 Nov/Dec; 24(6):406-415.
-
Anbalagan E, Ithman M, Lauriello J. Rechallenging clozapine after neuroleptic malignant syndrome. Psychiatr Q. 2014 Sep; 85(3):345-8.
-
Weaver LA, De León DD, Borgmann-Winter K, Coffey BJ. Use of metformin to control clozapine-associated weight gain in an adolescent with schizoaffective disorder. J Child Adolesc Psychopharmacol. 2010 Apr; 20(2):153-7.
-
Ahmed MR, Gurevich VV, Dalby KN, Benovic JL, Gurevich EV. Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation. J Pharmacol Exp Ther. 2008 Apr; 325(1):276-83.
-
Bustillo J, Wolff C, Myers-y-Gutierrez A, Dettmer TS, Cooper TB, Allan A, Lauriello J, Valenzuela CF. Treatment of rats with antipsychotic drugs: lack of an effect on brain N-acetyl aspartate levels. Schizophr Res. 2004 Jan 01; 66(1):31-9.
-
Bustillo JR, Lauriello J, Rowland LM, Jung RE, Petropoulos H, Hart BL, Blanchard J, Keith SJ, Brooks WM. Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. Psychiatry Res. 2001 Oct 01; 107(3):135-49.
-
Silverman BD, Pitman MC, Platt DE, Rigoutsos I. Molecular moment similarity between clozapine and substituted [(4-phenylpiperazinyl)-methyl] benzamides: selective dopamine D4 agonists. J Comput Aided Mol Des. 1998 Nov; 12(6):525-32.
-
Lauriello J, Mathalon DH, Rosenbloom M, Sullivan EV, Faustman WO, Ringo DL, Lim KO, Pfefferbaum A. Association between regional brain volumes and clozapine response in schizophrenia. Biol Psychiatry. 1998 Jun 15; 43(12):879-86.
-
Lauriello J, Jeste DV. Neuroleptic treatment of schizophrenia. Compr Ther. 1992 Jan; 18(1):30-5.